Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Kang Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0240-0908; OpenAlex author ID A5080777187. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2023: 3 papers · 2024: 3 papers · 2025: 5 papers · 2026: 1 paper

Papers 12

  1. Corrigendum to Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci211838↗
  2. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Co-author DOI 10.1002/cac2.70038↗
  3. [18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment. Co-author DOI 10.1007/s00259-025-07271-6↗
  4. Lactate metabolism reprogramming in PDAC: Potential for tumor therapy. First author DOI 10.1016/j.bbcan.2025.189373↗
  5. Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63146-2↗
  6. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci187024↗
  7. Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2024.101731↗
  8. ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion. Co-author DOI 10.1038/s41420-024-01862-2↗
  9. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Co-author DOI 10.1080/15548627.2023.2300913↗
  10. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Co-author DOI 10.1016/j.ymthe.2023.07.021↗
  11. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. Co-author DOI 10.1038/s41388-023-02711-9↗
  12. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Co-author DOI 10.1038/s41418-022-01102-z↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lihong He · 9 shared papers, 2023–2025 · strength 1.62
  2. Hanshen Yang · 8 shared papers, 2023–2025 · strength 1.37
  3. Xueli Bai · 8 shared papers, 2023–2025 · strength 1.37
  4. Xiaozhen Zhang · 7 shared papers, 2023–2025 · strength 1.36
  5. Mengyi Lao · 7 shared papers, 2023–2026 · strength 1.23
  6. Tingbo Liang · 7 shared papers, 2023–2025 · strength 1.15
  7. Tingbo Liang · 3 shared papers, 2024–2025 · strength 0.68
  8. Xiongbin Lu · 3 shared papers, 2025–2026 · strength 0.55
  9. Jian Xu · 3 shared papers, 2023–2024 · strength 0.49
  10. Qingbo Meng · 2 shared papers, 2024 · strength 0.41
  11. Xiao Zhi · 2 shared papers, 2025–2026 · strength 0.37
  12. Mao Ye · 2 shared papers, 2025–2026 · strength 0.37
  13. Jinyuan Song · 2 shared papers, 2025–2026 · strength 0.37
  14. Lingyue Liu · 2 shared papers, 2025 · strength 0.36
  15. Yan Chen · 2 shared papers, 2023–2025 · strength 0.34
  16. Xueli Bai · 1 shared paper, 2025 · strength 0.33
  17. Fan Gao · 1 shared paper, 2025 · strength 0.33
  18. Yi Duan · 2 shared papers, 2023 · strength 0.32
  19. Daqian Xu · 1 shared paper, 2025 · strength 0.22
  20. Xiang Li · 1 shared paper, 2025 · strength 0.22
  21. Lili Lin · 1 shared paper, 2025 · strength 0.22
  22. Xueli Bai · 1 shared paper, 2025 · strength 0.22
  23. Xinhui Su · 1 shared paper, 2025 · strength 0.22
  24. Tingbo Liang · 1 shared paper, 2026 · strength 0.20
  25. Junming Huang · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.